I. Adamová - Concepedia

Author

I. Adamová

Institute of Experimental Cardiology ORCID

Also Known As

Adamova IYu, I ADAMOVA, I Adamova, I Adamová, I Iu Adamova, I Yu Adamova, I. Adamova, I. Adamová, I. Y. Adamova, I. YU. Аdаmovа

Publications

728

Citations

H-Index

Concepts

All Affiliations

Institute of Experimental Cardiology Ministry of Health of the Russian Federation National Medical Research Center of Cardiology Bauman Moscow State Technical University Lomonosov Moscow State University

About

I. Adamová is an author at Institute of Experimental Cardiology specializing in medicine, atherosclerosis, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	428
2	Public Health	3	3	218
3	Health Sciences	2	2	64
4	Biochemistry	2	2	39
5	Engineering	1	1	22

I. Adamová

Publications

630

Citations

H-Index

Page 1

	Year	Citations
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography Maya Safarova, O. Afanasieva, Yuriy G. Matchin, Atherosclerosis Supplements Vascular DiseaseQuantitative Coronary AngiographyCardiovascular DiseaseMedicinePhysiology	2013	128
Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Alexander N. Orekhov, V.V. Tertov, Alexander E. Kabakov, Arteriosclerosis and Thrombosis A Journal of Vascular Biology Vascular DiseaseImmunologyPathologyHyperlipidemiaInflammation	1991	93
Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Alexander N. Orekhov, V.V. Tertov, S. Pokrovsky, Circulation Research Vascular DiseaseHealthy SubjectsPathologyHyperlipidemiaBiomedical Engineering	1988	71
Immunosorbent for Selective Removal of Lipoprotein (a) from Human Plasma: In Vitro Study S. Pokrovsky, I. Adamová, O. Afanasieva Artificial Organs	1991	45
Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data S. Pokrovsky, A. Sussekov, O. Afanasieva, Chemistry and Physics of Lipids Specific RemovalCardiovascular DiseaseImmunologyHematologyDyslipidemia	1994	39
The bacteriolytic activity of native and covalently immobilized lysozyme against Gram‐positive and Gram‐negative bacteria is differentially affected by charged amino acids and glycine D. A. Matolygina, I. Adamová, Sergey А. Smirnov, FEBS Open Bio	2019	39
Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity S. Pokrovsky, O. Afanasieva, Maya Safarova, Atherosclerosis Supplements Metabolic SyndromeSpecific LpPhysiologyHyperlipidemiaVascular Biology	2017	34
Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels Maya Safarova, O. Afanasieva, M. I. Tripoten, Atherosclerosis Supplements Metabolic SyndromeVascular DiseaseCardiovascular DiseaseMedicinePhysiology	2015	30
Development of Immunosorbents for apoB‐Containing Lipoproteins Apheresis S. Pokrovsky, Andrey V. Sussekov, I. Adamová, Artificial Organs	1995	24
Covalently immobilized chemically modified lysozyme as a sorbent for bacterial endotoxins (lipopolysaccharides) D. A. Matolygina, Dmitrieva Oa, I. Adamová, Biotechnology Reports Biofunctional MaterialEngineeringBiochemistryModified LysozymeBiochemical Engineering	2019	22

Page 1